Gw784752X

Gw784752X

SCHEMBL29534241

COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 20/20 1.00
GSK3A P49840 4/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gw784752X SCHEMBL8344352 1.00 GSK3B (1.00) GSK3BGSK3A
SCHEMBL8339760 0.92 GSK3B (1.00) GSK3BGSK3A
SCHEMBL8344607 0.91 GSK3B (0.84) GSK3BGSK3A
SCHEMBL8343169 0.90 GSK3B (0.82) GSK3BGSK3A
SCHEMBL8342451 0.90 GSK3B (0.82) GSK3BGSK3A
SCHEMBL8342769 0.90 GSK3B (1.00) GSK3BGSK3A
SCHEMBL8344429 0.90 GSK3B (1.00) GSK3BGSK3A
SCHEMBL8344464 0.89 GSK3B (1.00) GSK3BGSK3A
SCHEMBL8339151 0.89 GSK3B (0.81) GSK3BGSK3A
SCHEMBL8344582 0.89 GSK3B (0.89) GSK3BGSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066856-A1 PLATFORM AND SAMPLE TYPE INDEPENDENT SINGLE SAMPLE CLASSIFIER FOR TREATMENT DECISION MAKING IN PANCREATIC DUCTAL ADENOCARCINOMA CANCER THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2025-02-27 US disclosed
US-12000003-B2 Platform and sample type independent single sample classifier for treatment decision making in pancreatic ductal adenocarcinoma cancer THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2024-06-04 US disclosed
US-20220339154-A1 COMPOSITIONS, SYSTEMS, AND METHODS FOR GENERATING INNER EAR HAIR CELLS FOR TREATMENT OF HEARING LOSS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2022-10-27 US disclosed
US-20220259559-A1 COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY UPREGULATING JAG-1 Frequency Therapeutics, Inc. 2022-08-18 US disclosed
US-11369607-B2 Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2022-06-28 US disclosed
US-20220192984-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS Frequency Therapeutics, Inc. 2022-06-23 US disclosed
US-20220175776-A1 COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS Frequency Therapeutics, Inc. (US) 2022-06-09 US disclosed
US-20220170109-A1 PURITY INDEPENDENT SUBTYPING OF TUMORS (PURIST), A PLATFORM AND SAMPLE TYPE INDEPENDENT SINGLE SAMPLE CLASSIFIER FOR TREATMENT DECISION MAKING IN PANCREATIC CANCER THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2022-06-02 US disclosed
US-20220160664-A1 TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS UNITED STATES GOVERNMENT 2022-05-26 US disclosed
US-20220133740-A1 VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS Frequency Therapeutics, Inc. (US) 2022-05-05 US disclosed
US-20220127568-A1 COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY INHIBITING EPIGENETIC TARGETS Frequency Therapeutics, Inc. (US) 2022-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127568-A1 COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY INHIBITING EPIGENETIC TARGETS WNT3A, WNT1, MECP2 GSK3B 92/4885GSK3A 152/4885
US-20220339154-A1 COMPOSITIONS, SYSTEMS, AND METHODS FOR GENERATING INNER EAR HAIR CELLS FOR TREATMENT OF HEARING LOSS SHH, MYOC, HES1 GSK3B 1047/4885GSK3A 1335/4885
US-20220175776-A1 COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS HES1, SHH, HDAC11 GSK3B 678/4885GSK3A 732/4885
US-20220133740-A1 VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS WNT3A, WNT1, WNT3 GSK3B 42/4885GSK3A 24/4885
US-20220160664-A1 TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS WNT1, WNT3A, CTNNB1 GSK3B 63/4885GSK3A 66/4885
US-20220259559-A1 COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY UPREGULATING JAG-1 NOTCH1, HES1, NOTCH3 GSK3B 1102/4885GSK3A 1348/4885
US-11369607-B2 Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss SHH, MYOC, HES1 GSK3B 1047/4885GSK3A 1335/4885
US-20220192984-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS OTC, EXOSC5, ENTPD5 GSK3B 2670/4885GSK3A 2714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.